Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Jazz Pharma Plc (NQ: JAZZ ) 108.44 -1.26 (-1.15%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Jazz Pharma Plc < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > My Top Cannabis Stock to Buy in 2023 and Hold For 10 Years March 21, 2023 The cannabis sector has been disappointing in recent years, but this company stands out. Via The Motley Fool Medical Marijuana Milestone In The UK: Celadon Pharmaceuticals Becomes First Company With License To Sell In Britain March 14, 2023 Celadon Pharmaceuticals has become the first UK-based medical cannabis manufacturer to be granted a Home Office license to sell its products in the UK. Via Benzinga Silicon Valley Bank Failure Is Just The Tip Of Financial Iceberg, Could Affect Unexpected Industries March 14, 2023 Last week the US economy got clobbered by the biggest banking collapse since 2008 when the parent of Silicon Valley Bank, SVB Financial Group (NASDAQ: SIVB) failed to raise enough capital to continue. Via Benzinga Zymeworks Offers Hope for More than Just Long-Term Investors March 09, 2023 Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher Via MarketBeat With Access To $20 Million In Financing, 1606 Corp Is Eyeing CBD Business Acquisitions As It Embarks On An Aggressive Growth Path March 08, 2023 The global CBD market is on an upward trajectory, and there are no indications that the growth could be slowing down anytime soon. The market was valued at $5.18 billion in 2021 and is expected to... Via Benzinga The Latest Analyst Ratings for Jazz Pharmaceuticals March 06, 2023 Via Benzinga Earnings Scheduled For March 1, 2023 March 01, 2023 Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. Via Benzinga Earnings Preview For Jazz Pharmaceuticals February 28, 2023 Via Benzinga Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying March 07, 2023 The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various... Via Benzinga Why Cannabis Is Recession-Resistant & Turning Challenges Into Opportunities, Industry Expert Explains March 02, 2023 It is safe to say that the cannabis industry would not have progressed as much as it has if it were not for the people who believed in it. Cannabis advocates, lobbyists, growers, operators, consumers... Via Benzinga Jazz Q4 2022 Revenue Grows 8% To $972M, Provides Outlook March 02, 2023 Jazz Pharmaceuticals plc (NASDAQ: JAZZ) Q4 2022 revenue was $972.12 million an 8% increase compared to 896.73 million in Q4 2021. Financial Highlights Via Benzinga Cannabis-Based Medicine As A Potential Treatment For Psychosis, An Oxford University Study Says February 17, 2023 The Department of Psychiatry at the University of Oxford will conduct an international study to investigate whether cannabis-based medicine can treat psychosis. Via Benzinga Teva Plots Its Knockoff Of Axsome's New Depression Drug, Sending The Biotech Sprawling February 13, 2023 The company only just gained approval for its depression drug in August. Via Investor's Business Daily Will Investors Notice Exciting Sign On Jazz Pharmaceuticals's Chart? January 06, 2023 Via Benzinga 2 Cannabis Stocks to Buy for the Long Haul December 31, 2022 Don't give up on this sector too quickly. Via The Motley Fool Jazz Pharma Opts In, Advances Zanidatamab Partnership With Zymeworks December 21, 2022 Via Benzinga GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow February 13, 2023 Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of... Via Talk Markets 2 Cannabis Stocks That Could Make You Richer February 09, 2023 These two stocks could grow like weeds in the next five years and beyond. Via The Motley Fool CBD-Based Life-Changing Drug For Tuberous Sclerosis Patients, Epidiolex, Now Available Via England's NHS February 02, 2023 The National Health Service England confirmed Tuesday that starting this week, doctors can prescribe Jazz Pharmaceuticals (NASDAQ: JAZZ) Epidiolex, a CBD-based medicine, to patients suffering from... Via Benzinga 3 Cannabis Stocks With Double-Digit Percentage Revenue Growth January 30, 2023 Their shares may be down, but their sales are up. Via The Motley Fool The Ultimate Growth Stocks to Buy With $300 Right Now January 29, 2023 These three companies should deliver inflation-busting long-term growth. Via The Motley Fool 2 Promising New Growth Stocks to Watch in 2023 January 23, 2023 These stocks have plenty of room to run. Via The Motley Fool Jazz Pharma, Zymeworks Highlight 84% Overall Survival At 18 Months From Zanidatamab In Esophageal Cancer January 19, 2023 Via Benzinga 2 Stocks That Beat the Market in 2022 and That Analysts Think Can Go Higher January 11, 2023 There are still plenty of growth opportunities left for these businesses. Via The Motley Fool These Stocks Jumped 100% and 30% Last Year. Here's Why They're Still a Buy. January 07, 2023 These stocks look cheap if you take a long-term view. Via The Motley Fool Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court January 05, 2023 Jazz Pharmaceuticals (NASDAQ: JAZZ), a drug company behind the CBD-based medication Epidiolex, recently filed a lawsuit against Teva Pharmaceutical Industries Ltd (NYS Via Benzinga 2 Growth Stocks to Buy Heading Into 2023 December 30, 2022 These biotechs are far from having achieved their full potential. Via The Motley Fool 2 Top Biotech Stocks to Buy for the Long Haul December 25, 2022 These mid-cap biotechs are solid long-term choices. Via The Motley Fool Better Buy: Moderna vs Axsome December 22, 2022 Revenue prospects look promising for both of these biotech companies. Via The Motley Fool Tesla, Amazon, Micron, Sintx, Zymeworks: Why These 5 Stocks Are Drawing Investors' Attention Today December 21, 2022 U.S. markets soared on Wednesday as consumer confidence surged to an eight-month high in December following a drop in inflation and the labor market remaining strong. Twelve-month inflation... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 11 12 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.